Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals, Inc. (ARWR) is a healthcare company (biotechnology) based in the United States. The share price is $43.22, down 2.24% on the day, which values the company at $6.11B. Price as of 17 Nov 2026, 17:22 UTC, from Yahoo Finance.

Key facts

Share price
$43.22−2.24% today
Market value
$6.11B
Funk Score
31/100
Against its own history
Above its usual priceusual price $34.49
200-week average
$37.1616% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Arrowhead Pharmaceuticals, Inc. in more detail

ARWR trades at -12.0× next year's expected earnings, 13.6× sales. Measured against its own history, the price is 25% above what its usual multiples would imply ($34.49) — above its usual price. It sits 16% above its 200-week average of $37.16.

Over the last five fiscal years Arrowhead Pharmaceuticals, Inc. has compounded revenue 26.7% a year. Its Funk Score is 31 out of 100 (financial strength 2.8, profitability 0.3, growth 8.0, value 1.4, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

2 of the superinvestors tracked here hold ARWR, including Julian and Felix Baker (0.8% of the portfolio), Brandon Haley (0.2% of the portfolio).

Superinvestors holding ARWR

2 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:ARWR vs ORKA (Arrowhead Pharmaceuticals, Inc. vs Oruka Therapeutics)ARWR vs CHE (Arrowhead Pharmaceuticals, Inc. vs Chemed)ARWR vs AXSM (Arrowhead Pharmaceuticals, Inc. vs Axsome Therapeutics)ARWR vs MSA (Arrowhead Pharmaceuticals, Inc. vs MSA Safety)ARWR vs CGON (Arrowhead Pharmaceuticals, Inc. vs CG Oncology)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Arrowhead Pharmaceuticals, Inc. (ARWR): questions and answers

What is Arrowhead Pharmaceuticals, Inc.'s market cap?

Arrowhead Pharmaceuticals, Inc. is valued at $6.11B at a share price of $43.22.

Is ARWR overvalued or undervalued?

Against its own history, ARWR is above its usual price: the price is 25% above the $34.49 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is ARWR above its 200-week moving average?

Yes. ARWR is 16.3% above its 200-week average of $37.16. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Arrowhead Pharmaceuticals, Inc. growing?

Over the last five fiscal years Arrowhead Pharmaceuticals, Inc.'s revenue grew 26.7% a year; over ten years revenue grew 121.5% a year.

Does ARWR pay a dividend?

Arrowhead Pharmaceuticals, Inc. does not currently pay a regular dividend.

Which famous investors own ARWR?

In their latest quarterly filings, Julian and Felix Baker (0.8% of the portfolio), Brandon Haley (0.2% of the portfolio) hold ARWR. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Arrowhead Pharmaceuticals, Inc. (ARWR) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ARWR

Underlying data: Yahoo Finance; company filings with the SEC.